GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,708.60p
   
  • Change Today:
      3.40p
  • 52 Week High: 1,713.00p
  • 52 Week Low: 1,316.00p
  • Currency: UK Pounds
  • Shares Issued: 4,144.88m
  • Volume: 7,547,306
  • Market Cap: £70,819m
  • RiskGrade: 129

Oxford University's push for Covid-19 vaccine may stumble due to drop in infections

By Alexander Bueso

Date: Tuesday 26 May 2020

LONDON (ShareCast) - (Sharecast News) - Oxford University's attempts to develop a vaccine against the novel coronavirus could run into an apparently unexpected hurdle, the head of its research team said.
Regardless of how effective the vaccine might be, if the number of Covid-19 cases in Britain continue to fall, that could make it impossible to interpret the results from the human trials now under way.

In remarks to the Telegraph, at the weekend, Professor Adrian Hill said: "It's a race against the virus disappearing, and against time.

"We said earlier in the year that there was an 80% chance of developing an effective vaccine by September. But at the moment, there's a 50% chance that we get no result at all."

According to Hill, who is also the director of the university's Jenner Institute, less than 50 of the 10,000 volunteers participating in the trial will get become infected with the coronavirus.

But if fewer than 20 do so then the results may be useless, he reportedly added.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,708.60p
Change Today 3.40p
% Change 0.20 %
52 Week High 1,713.00p
52 Week Low 1,316.00p
Volume 7,547,306
Shares Issued 4,144.88m
Market Cap £70,819m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
83.07% below the market average83.07% below the market average83.07% below the market average83.07% below the market average83.07% below the market average
55.56% below the sector average55.56% below the sector average55.56% below the sector average55.56% below the sector average55.56% below the sector average
Price Trend
50.74% above the market average50.74% above the market average50.74% above the market average50.74% above the market average50.74% above the market average
71.93% above the sector average71.93% above the sector average71.93% above the sector average71.93% above the sector average71.93% above the sector average
Income
31.40% above the market average31.40% above the market average31.40% above the market average31.40% above the market average31.40% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average
Growth
26.72% below the market average26.72% below the market average26.72% below the market average26.72% below the market average26.72% below the market average
29.73% above the sector average29.73% above the sector average29.73% above the sector average29.73% above the sector average29.73% above the sector average

What The Brokers Say

Strong Buy 7
Buy 6
Neutral 9
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 22-Feb-24 16-Nov-23
Paid 11-Apr-24 11-Jan-24
Amount 16.00p 14.00p

Trades for 28-Mar-2024

Time Volume / Share Price
17:14 750,000 @ 1,709.81p
17:04 13,917 @ 1,706.01p
17:04 13,076 @ 1,706.01p
17:04 549 @ 1,706.01p
17:03 172,458 @ 1,706.01p

GSK Key Personnel

CEO Emma Walmsley

Top of Page